ARTICLES BY C. RAJAN
-
Lundbeck Extends Ossianix Research Collaboration To Develop New CNS Therapeutics12/26/2014
Denmark-based drugmaker Lundbeck has extended its research collaboration with U.S. based drug discovery and development company, Ossianix, to develop next generation CNS biotherapeutics.
-
Novogen's Brain Cancer Drug Also Active Against Melanoma12/22/2014
Australian biotech firm, Novogen, has announced a “breakthrough” discovery in melanoma treatment, as the company’s lead candidate, TRXE-009, was found to be highly active against melanoma in pre-clinical studies.
-
Ultragenyx Begins Phase 3 Study Of Recombinant Human Beta-Glucuronidase In Sly Syndrome12/18/2014
California based Ultragenyx Pharmaceutical has announced the initiation of a pivotal Phase 3 study of recombinant human beta-glucuronidase (rhGUS, UX003) for the treatment of Sly syndrome (Mucopolysaccharidosis 7 or MPS 7).
-
Alkermes Begins Schizophrenia Clinical Trial Of Extended Duration Aripiprazole Lauroxil12/18/2014
Dublin-based drugmaker Alkermes has announced that it will begin a phase 1 clinical trial to investigate the effect of extended dosing intervals of aripiprazole lauroxil on schizophrenia.
-
ChemoCentryx's CCR2 inhibitor Succeeds In Phase 2 Diabetic Nephropathy Trial12/18/2014
California-based biotech company, ChemoCentryx, has announced positive results from its Phase 2 clinical trial of a novel CCR2 inhibitor, CCX140, in patients with diabetic nephropathy.
-
Eisai's Eribulin Combination Therapy Succeeds In Metastatic Breast Cancer Phase 2 Study12/16/2014
Eisai has announced that its halichondrin drug, Eribulin (Halaven) in combination with capecitabine, provided significant clinical benefit to women with metastatic breast cancer in a Phase 2 study, suggesting that this combination could be a useful adjuvant treatment option in women with early HER2-Normal/HER2 Negative and ER positive breast cancer.
-
New Parkinson's Vaccine Enters Clinical Trial In Europe12/15/2014
Austrian biotech company, AFFiRiS AG, has announced that a novel Parkinson's vaccine candidate, AFFITOPE PD03A, will be tested in a Phase 1 clinical trial in Austria soon.
-
Bluebird's Gene Therapy Cures Blood Disorder In Phase 1/2 Trial12/15/2014
Gene therapy company, Bluebird Bio, has announced exciting results of its LentiGlobin BB305 drug product in a Phase 1/2 study in patients with beta-thalassemia major, a deadly genetic blood disorder.
-
AbbVie's AML Drug Shows Positive Results In Phase 2 Study12/11/2014
AbbVie has announced the positive results of its investigational drug, Venetoclax, from a Phase 2 clinical trial in patients with acute myelogenous leukemia (AML). The company presented the study results at the American Society of Hematology's (ASH) 56th Annual Meeting in California this week.
-
Cynapsus' Parkinson's Disease Therapy Succeeds In Phase 2 Study11/26/2014
Cynapsus Therapeutics has announced positive results from the Phase 2 clinical trial of its lead candidate, APL-130277, for treating OFF motor symptoms of Parkinson’s disease.
-
New Study IDs Key Methods To Boost Clinical Trial Awareness, Diversity11/17/2014
Researchers at The University of Texas Health Science Center at San Antonio have found a new method to increase the diversity of study populations in clinical trials, in particular for Latinos who participate in disproportionately low numbers in cancer clinical trials in the United States.
-
Spark Therapeutics' Gene Therapy Gets FDA Breakthrough Therapy Designation11/12/2014
Gene therapy company Spark Therapeutics has received the U.S. FDA’s coveted breakthrough therapy designation for its lead product candidate, SPK-RPE65, for the treatment of inherited blindness caused by mutations of the RPE65 gene.
-
Lundbeck's Aripiprazole Beats Competition In Novel Head-to-Head Study11/10/2014
Danish biotech firm Lundbeck and its partner Otsuka have announced the positive results from a first-of-its-kind study of their schizophrenia drug aripiprazole (Abilify Maintena), which was pitted up against Janssen’s paliperidone palmitate (Invega Sustena).
-
Drug Combo Improves Survival In Advanced Melanoma Patients11/10/2014
A new study finds that patients with advanced metastatic melanoma survived longer when treated with a combination of an immune system booster and a standard cancer drug.
-
Medivation And Astellas' Prostate Cancer Drug To Enter Phase 3 Trial For New Indication11/6/2014
Medivation and Astellas have announced they will be moving their jointly developed prostate cancer drug, enzalutamide, into a new Phase 3 clinical trial for high-risk, hormone-sensitive, non-metastatic prostate cancer that has biochemically recurred after local therapy. There is no approved medicine for this indication in the U.S. to date.